• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS

Monday, June 03, 2024
Breakout Session
Cell and Gene Therapy and Genome Editing
31AB
Cell and gene-based therapies and their potential to cure disease after a single course of therapy have revolutionized the way biopharmaceutical companies are addressing treatment. While the science behind them is revolutionary, their costs have raised concerns. How will state Medicaid agencies address the budgeting challenges that the new therapies pose? What do manufacturers, states, and patients need from CMS? Join this interactive panel for a look at the prospects and obstacles associated with these therapies, including what payment models will facilitate broader use of cell and gene therapies; how state Medicaid programs are addressing the challenges posed by these innovative yet costly therapies and, what potential actions the U.S. Centers for Medicare & Medicaid Services can take to encourage wider adoption.
Moderator
Thomas Barker
Partner
Foley Hoag LLP
Speakers
Scott McGoohan, JD
Executive Director, Policy and Alliance Development
Vertex Pharmaceuticals
Jay Newman
SVP, Commercial Development, Pricing & Reimbursement
Spark Therapeutics, Inc.
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS